Phase II trial of daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering multiple myeloma

被引：0
|
作者：
Nadeem, Omar [1 ]
Redd, Robert [1 ]
Mo, Clifton [1 ]
Laubach, Jacob [1 ]
Richardson, Paul G. [1 ]
Prescott, Julia [1 ]
Marto, Marjorie [1 ]
Davie, Christine [1 ]
Ricciardi, Caroline [1 ]
Murphy, Elizabeth [1 ]
Bertoni, Meredith [1 ]
Choden, Dechen [1 ]
Magidson, Sophie [1 ]
Sheehan, Brian [1 ]
Shrestha, Hira [1 ]
Sperling, Adam S. [1 ]
O'Donnell, Elizabeth K. [2 ]
Ghobrial, Irene M. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-099
引用
收藏
页码：S89 / S89
页数：1
相关论文
共 50 条
  • [31] Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
    Derman, Benjamin A.
    Cooperrider, Jennifer
    Rosenblatt, Jacalyn
    Avigan, David E.
    Rampurwala, Murtuza
    Barnidge, David
    Major, Ajay
    Karrison, Theodore
    Jiang, Ken
    Ramsland, Aubrianna
    Kubicki, Tadeusz
    Jakubowiak, Andrzej J.
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [32] Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
    Nooka, A. K.
    Kaufman, J. L.
    Muppidi, S.
    Langston, A.
    Heffner, L. T.
    Gleason, C.
    Casbourne, D.
    Saxe, D.
    Boise, L. H.
    Lonial, S.
    LEUKEMIA, 2014, 28 (03) : 690 - 693
  • [33] Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
    A K Nooka
    J L Kaufman
    S Muppidi
    A Langston
    L T Heffner
    C Gleason
    D Casbourne
    D Saxe
    L H Boise
    S Lonial
    Leukemia, 2014, 28 : 690 - 693
  • [34] Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
    Facon, Thierry
    Dimopoulos, Meletios-Athanasios
    Leleu, Xavier P.
    Beksac, Meral
    Pour, Ludek
    Hajek, Roman
    Liu, Zhuogang
    Minarik, Jiri
    Moreau, Philippe
    Romejko-Jarosinska, Joanna
    Spicka, Ivan
    Vorobyev, Vladimir I.
    Besemer, Britta
    Ishida, Tadao
    Janowski, Wojciech
    Kalayoglu-Besisik, Sevgi
    Parmar, Gurdeep
    Robak, Pawel
    Zamagni, Elena
    Goldschmidt, Hartmut
    Martin, Thomas G.
    Manier, Salomon
    Mohty, Mohamad
    Oprea, Corina
    Bregeault, Marie-France
    Mace, Sandrine
    Berthou, Christelle
    Bregman, David
    Klippel, Zandra
    Orlowski, Robert Z.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (17): : 1597 - 1609
  • [35] A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety
    Nadeem, Omar
    Redd, Robert
    Stampleman, Laura V.
    Matous, Jeffrey V.
    Yee, Andrew J.
    Zonder, Jeffrey A.
    Kin, Andrew
    Rosenblatt, Jacalyn
    Bustoros, Mark
    Prescott, Julia
    Savell, Alexandra
    Guimond, Kathleen
    Frey, Erin
    Styles, Rachel
    Bielawski, Adrienne
    Boehner, Cody J.
    Kham, Nang
    Sperling, Adam S.
    Bianchi, Giada
    Laubach, Jacob P.
    Castillo, Jorge J.
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Trippa, Lorenzo
    Ghobrial, Irene M.
    BLOOD, 2019, 134
  • [36] OPTIMUM/MUKnine trial: Extended post-ASCT consolidation with Daratumumab, Bortezomib, Lenalidomide and dexamethasone for Ultra-high risk myeloma
    Jenner, Matthew
    Hall, Andrew
    Smith, Isabelle
    de Tute, Ruth
    Roberts, Sadie
    Pratt, Guy
    Drayson, Mark
    Owen, Roger
    Brown, Sarah
    Kaiser, Martin
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 18 - 19
  • [37] Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial
    Usmani, Saad Z.
    Hoering, Antje
    Ailawadhi, Sikander
    Sexton, Rachael
    Lipe, Brea
    Hita, Sandi Fredette
    Valent, Jason
    Rosenzweig, Michael
    Zonder, Jeffrey A.
    Dhodapkar, Madhav
    Callander, Natalie
    Zimmerman, Todd
    Voorhees, Peter M.
    Durie, Brian
    Rajkumar, S. Vincent
    Richardson, Paul G.
    Orlowski, Robert Z.
    LANCET HAEMATOLOGY, 2021, 8 (01): : E45 - E54
  • [38] Smoldering multiple myeloma associated with a acquired von Willebrand syndrome, successfully treated by daratumumab, lenalidomide and dexamethasone
    Iarossi, Michael
    Vekemans, Marie-Christiane Madeleine
    Weynants, Nicolas
    Hermans, Cedric
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S276 - S276
  • [39] Acquired von Willebrand Syndrome Associated with a Smoldering Multiple Myeloma, Successfully Treated by Daratumumab, Lenalidomide, and Dexamethasone
    Iarossi, Michael
    Vekemans, Marie-Christiane Madeleine
    Weynants, Nicolas
    Hermans, Cedric
    ACTA HAEMATOLOGICA, 2024, 147 (05) : 587 - 591
  • [40] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Yasuo Mori
    Ilseung Choi
    Goichi Yoshimoto
    Tsuyoshi Muta
    Satoshi Yamasaki
    Kazuki Tanimoto
    Tomohiko Kamimura
    Hiromi Iwasaki
    Ryosuke Ogawa
    Koichi Akashi
    Toshihiro Miyamoto
    International Journal of Hematology, 2020, 111 : 673 - 680
12345